Lundbeckfonden Ventures News

Lund, Sweden, (PRNEWSWIRE) April 29, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENTT'V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENTT'V...
Novel formulation and proprietary patch pump would offer a new and different option for the management of fluid overload in heart failure.
Cambridge, UK - 21st April 2015: Acacia Pharma Ltd (Acacia Pharma" or "the Company"), the supportive care company developing  products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard antiemetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a...
OXFORD, UK - 16 April 2015 - PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will present data highlighting the progress of its next generation Antibody Armed EnAd" (AbEnAd) anti-cancer therapeutic platform at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA April 19-22, 2015. AbEnAd is...
Phase I Study Results Confirming Intravenous Delivery Profile and Repeated Dosing Leads to Expansion of the Clinical Programme into New Indications
Financing will be used to grow CERAMENTT platform and expand market penetration
LEXINGTON, Mass., April 14, 2015 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that it has elected Dorothy A. Coleman to its board of directors and that it has appointed Brian Piekos as Chief Financial Officer. 
SAN DIEGO and POMPEY, France, March 24, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company and Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming...
Niemann-Pick Disease experts Drs. Paul Gissen, Marc Patterson and Forbes D. Porter, along with biopharmaceutical industry leader Dr. Cristina Csimma, join Vtesse in quest to develop new treatments for people facing Niemann-Pick Disease Type C and rare diseasesGAITHERSBURG, Md., March 25, 2015 /PRNewswire/ -- Vtesse, Inc.,  a rare disease company focused on developing drugs for Niemann-Pick Disease...
1 40 41 42 43 44 63

Lundbeckfonden Ventures


First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis
17. February 2020
Spero Therapeutics Announces Commencement of Rights Offering
11. February 2020
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
5. February 2020